-
Tytuł:
-
Influencing factors of end-of-dose failure in patients with cancer pain after oral oxycodone sustained-release tablets: a retrospective, case-control study.
-
Autorzy:
-
Huang HX; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.; Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Liu KK; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.; Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhang L; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.; Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Huang YM; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.; Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Liu WH; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Xiao J; Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.; Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
-
Źródło:
-
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 May 28; Vol. 51 (6), pp. 932-941.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Oxford : Oxford University Press
Original Publication: Tokyo, Foundation of Clinical Oncology.
-
MeSH Terms:
-
Cancer Pain/*drug therapy
Delayed-Action Preparations/*therapeutic use
Oxycodone/*therapeutic use
Tablets/*therapeutic use
Administration, Oral ; Case-Control Studies ; Delayed-Action Preparations/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Oxycodone/pharmacology ; Retrospective Studies ; Tablets/pharmacology
-
Contributed Indexing:
-
Keywords: cancer pain; end-of-dose failure; influencing factors; oxycodone sustained-release tablets
-
Substance Nomenclature:
-
0 (Delayed-Action Preparations)
0 (Tablets)
CD35PMG570 (Oxycodone)
-
Entry Date(s):
-
Date Created: 20210201 Date Completed: 20210611 Latest Revision: 20210611
-
Update Code:
-
20240104
-
DOI:
-
10.1093/jjco/hyab002
-
PMID:
-
33521814
-
Objective: Comparing the characteristics of end-of-dose failure patients and non-end-of-dose failure patients in the Chinese population and exploring the factors that may affect the occurrence of end-of-dose failure in cancer pain patients.
Methods: The outpatient with cancer pain from 2016 to 2019 were collected through hospital information system, and patients were included who met the following criteria: patients with the average numerical rating scale ≥4 points within 3 days after taking the oxycodone sustained-release preparation, titrated to an effective therapeutic dose suitable for patients, had at least two clinical visits information of the patient with a minimum of ≥3 days between visits, the average numerical rating scale of the next visit after the treatment of occasional pain is ≥4, and were divided into end-of-dose failure group and non-end-of-dose failure group.
Results: Age (P < 0.05, odds ratio 0.933), diagnosis of nasopharyngeal carcinoma (P < 0.05, odds ratio 0.009), pain site is the head and neck (P < 0.05, odds ratio 0.005) and the abdomen (P < 0.01, odds ratio 0.021), and the metastatic site is the liver (P < 0.05, odds ratio 0.001) are related to the occurrence of end-of-dose failure.
Conclusions: Younger patients are more likely to develop end-of-dose failure. Patients diagnosed with nasopharyngeal cancer, with pain in the head and neck and abdomen, and with liver metastases have a lower incidence of end-of-dose failure.
(© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.)
